Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01439152 · ClinicalTrials.gov registry record · Phase 1
Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.
A Phase 1 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 148
- Enrollment target
NCT01439152: Completed Phase 1 study, sponsored by Bayer.
NCT01439152 is a Phase 1 study that has completed, run by Bayer. The registered enrollment target is 148 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (147% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01439152, a Phase 1 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 148 participants
- Enrollment target
Study Summary
BAY94-9343 was an antibody-drug conjugate (ADC) directed against the cancer antigen mesothelin on tumor cells.
Interventions
- DRUG BAY94-9343
- DRUG BAY94-9343 (Expansion)
- DRUG BAY94-9343 (1.8 mg/kg)
- DRUG BAY94-9343 (2.2 mg/kg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2011-09-07 |
| Est. Completion | 2019-07-30 |
| Phase | Phase 1 |
What the finished NCT01439152 record still lists
NCT01439152 is an interventional study that assigns participants to a tested intervention. The registered 148 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (147% higher).
The record links to 0 conditions, and to 4 interventions - of which BAY94-9343 is the first listed.
NCT01439152 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01439152 about?
NCT01439152 is a clinical study titled "Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.". BAY94-9343 was an antibody-drug conjugate (ADC) directed against the cancer antigen mesothelin on tumor cells.
What is the current status of trial NCT01439152?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 148 participants. The study started on 2011-09-07. Estimated completion is 2019-07-30.
What interventions are being tested in trial NCT01439152?
The interventions under investigation include: BAY94-9343 (DRUG), BAY94-9343 (Expansion) (DRUG), BAY94-9343 (1.8 mg/kg) (DRUG), BAY94-9343 (2.2 mg/kg) (DRUG).
Who is sponsoring clinical trial NCT01439152?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01439152's enrollment target sits among peer trials
148 382nd of 2000 higher than 1,614 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00739362 · 148 participants · Phase 2
Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment
- NCT03161223 · 148 participants · Phase 1
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
- NCT03858231 · 148 participants · Phase 4
Opioids Versus Non-Opioids Postoperative After Knee Arthroscopic Surgery
- NCT04486352 · 148 participants · Phase 1
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI